Market news

Let’s dig into the relative performance of Integra LifeSciences (NASDAQ:IART) and its peers as we unravel the now-completed Q2 surgical equipment & consumables - specialty earnings season.

PRINCETON, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that Lea Knight, chief financial officer, and Michael McBreen, chief commercial officer, will present at the 2026 Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 2:15 p.m. ET. Stuart Essig, chairman and chief executive officer, will present at the 2026 Morgan Stanley Healthcare Conference on Tuesday, Septe

Detailed price information for Trupanion Inc (TRUP-Q) from The Globe and Mail including charting and trades.

Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Integra's SurgiMend relaunch could support a broader 2027 recovery, but customer recapture and FDA approval remain key to the upside.

Detailed price information for Sm Energy Company (SM-N) from The Globe and Mail including charting and trades.

Detailed price information for Belden Inc (BDC-N) from The Globe and Mail including charting and trades.

Integra LifeSciences Holdings earnings and guidance draw investor focus Integra LifeSciences Holdings (IART) has come back into focus after reporting second quarter 2026 results with a swing back to profitability, while also updating quarterly and full year revenue guidance on July 29. The company reported second quarter sales of US$418.76 million compared with US$415.61 million a year earlier. Net income was US$4.48 million compared with a net loss of US$484.07 million in the prior year...

Integra LifeSciences Holdings reported past second-quarter 2026 results with sales of US$418.76 million and net income of US$4.48 million, and issued third-quarter revenue guidance of US$410 million to US$425 million while slightly trimming its full-year 2026 outlook to US$1.65 billion to US$1.70 billion due to currency effects. The swing from a very large prior-year net loss to a modest profit, while maintaining overall revenue guidance, points to meaningful operational and earnings quality...

Tipranks Press Release.

Shares of medical device company Integra LifeSciences (NASDAQ:IART) fell 10.1% in the afternoon session after the company reported a second-quarter earnings beat was overshadowed by concerns about flat revenue growth and declining profitability.

Detailed price information for Integra Lifesciences (IART-Q) from The Globe and Mail including charting and trades.

Bassett Furniture, Aveanna Healthcare and Integra LifeSciences are highlighted as potential breakout stocks using support and resistance levels ahead of August.

Detailed price information for Integra Lifesciences (IART-Q) from The Globe and Mail including charting and trades.

Moby summary of Integra LifeSciences Holdings Corporation's Q2 2026 earnings call

Integra (IART) delivered earnings and revenue surprises of +16.67% and -0.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

PRINCETON, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2026. Second Quarter 2026 Highlights Second quarter revenues of $418.8 million increased 0.8% on a reported basis and 0.7% on an organic basis compared to the prior year. Second quarter GAAP earnings per diluted share of $0.06, compared to $(6.31) in the prior year. Adjuste

Medical device company Integra LifeSciences (NASDAQ:IART) met Wall Street’s revenue expectations in Q2 CY2026, but sales were flat year on year at $418.8 million. The company expects next quarter’s revenue to be around $417.5 million, close to analysts’ estimates. Its non-GAAP profit of $0.56 per share was 15.8% above analysts’ consensus estimates.

Integra LifeSciences (NASDAQ:IART) reported second-quarter 2026 revenue of $419 million, up 0.8% on a reported basis and 0.7% organically from a year earlier, as improving supply reliability and operational execution supported results. Adjusted earnings per share rose 24% year over year to $0.56, ex

While the top- and bottom-line numbers for Integra (IART) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Medical device company Integra LifeSciences (NASDAQ:IART) will be announcing earnings results this Wednesday morning. Here’s what to look for.

Detailed price information for Integra Lifesciences (IART-Q) from The Globe and Mail including charting and trades.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 9.7% over the past six months, topping the S&P 500 by 1.8 percentage points.

Integra LifeSciences Holdings recently drew attention after a run of earnings beats and favorable analyst assessments coincided with preparations for its second-quarter 2026 results release and conference call, now in the past. The combination of a consistent pattern of topping earnings expectations and upward estimate revisions has reinforced investor confidence in the company’s operational execution. Next, we will examine how this earnings outperformance track record shapes Integra...

Integra LifeSciences Holdings has rebounded sharply in the past year after a difficult few years, and at the current US$19.85 share price both the Discounted Cash Flow (DCF) intrinsic value estimate and the market multiples still indicate the stock is trading at a discount to what the business may be worth. Over the past 5 years the stock has fallen 70.4%, which means the recent strength comes after a long period of weak returns for longer term holders. The business can support its valuation...

PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release second quarter 2026 financial results on Wednesday, July 29, 2026, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company’s website at investor.integralife.com. For those plann

Integra (IART) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Detailed price information for Integra Lifesciences (IART-Q) from The Globe and Mail including charting and trades.